人源 CAR-T22.19 治疗难治性儿童 B-ALL：指定患者队列的启示

Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort.

CAR-T22.19 疗法在高危儿科人群中显示出良好的安全性特征和有前景的临床活性，其双靶向设计使 CD19 阴性白血病获得疾病控制。

NKTR-255 联合 CD19-22 CAR-T 细胞疗法治疗难治性 B 细胞急性淋巴细胞白血病的 1 期临床试验

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.

靶向 CD19/20 的双特异性 CAR-T 细胞治疗复发/难治性 B 细胞非霍奇金淋巴瘤患者：一项 I/II 期试验

Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial.

共转导 CAR-T 细胞靶向 CD19/CD22 预防 B 细胞 ALL 的 CAR-T 治疗后抗原阴性复发

CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.

CD19/CD22 双特异性 CAR-T 细胞治疗 MRD 阳性成人 B 细胞急性淋巴细胞白血病：一项 I 期临床研究

CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study.

利用新型高灵敏度 aCD22 CAR 双靶向 CD19 与 CD22 治疗 B-ALL

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.

CD34+CD19-CD22+ B 细胞祖细胞可能构成 CD19 靶向治疗患者表型逃逸的基础

CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.

双靶向 CD19 和 CD22 的 CAR-T 细胞治疗儿童和年轻成人复发/难治性 B 细胞急性淋巴细胞白血病：一项 1 期试验

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia

探索双特异性 CAR-T 细胞治疗急性白血病的当前证据：一项系统综述

Exploring current evidence on bispecific CAR-T cell therapy for acute leukemias: a systematic review.

双特异性 CAR-T 细胞疗法在管理急性白血病方面比传统 CAR-T 细胞更有效。未来的研究应侧重于开发多样化的靶点并推进至临床试验。

从全血高效制备 CAR-T 细胞：降低肿瘤治疗成本并提升可及性的可扩展方案

Efficient manufacturing of CAR-T cells from whole blood: a scalable approach to reduce costs and enhance accessibility in cancer therapy.

可从全血中成功制备具有治疗相关剂量的 CD19/CD22 CAR-T 细胞。